CA2575329A1 - Indole, indazole or indoline derivatives - Google Patents

Indole, indazole or indoline derivatives Download PDF

Info

Publication number
CA2575329A1
CA2575329A1 CA002575329A CA2575329A CA2575329A1 CA 2575329 A1 CA2575329 A1 CA 2575329A1 CA 002575329 A CA002575329 A CA 002575329A CA 2575329 A CA2575329 A CA 2575329A CA 2575329 A1 CA2575329 A1 CA 2575329A1
Authority
CA
Canada
Prior art keywords
ethyl
phenyl
mmol
tert
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002575329A
Other languages
English (en)
French (fr)
Inventor
Aurelia Conte-Mayweg
Holger Kuehne
Thomas Luebbers
Cyrille Maugeais
Werner Mueller
Philippe Pflieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2575329A1 publication Critical patent/CA2575329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CA002575329A 2004-08-05 2005-07-27 Indole, indazole or indoline derivatives Abandoned CA2575329A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103762 2004-08-05
EP04103762.3 2004-08-05
PCT/EP2005/008142 WO2006013048A1 (en) 2004-08-05 2005-07-27 Indole, indazole or indoline derivatives

Publications (1)

Publication Number Publication Date
CA2575329A1 true CA2575329A1 (en) 2006-02-09

Family

ID=35448129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002575329A Abandoned CA2575329A1 (en) 2004-08-05 2005-07-27 Indole, indazole or indoline derivatives

Country Status (13)

Country Link
US (1) US7259183B2 (zh)
EP (1) EP1776338A1 (zh)
JP (1) JP4787254B2 (zh)
KR (1) KR100854864B1 (zh)
CN (1) CN1993323B (zh)
AR (1) AR050281A1 (zh)
AU (1) AU2005268893B2 (zh)
BR (1) BRPI0514133A (zh)
CA (1) CA2575329A1 (zh)
MX (1) MX2007001431A (zh)
RU (1) RU2007106180A (zh)
TW (1) TW200616953A (zh)
WO (1) WO2006013048A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960350B1 (en) * 2005-11-22 2015-08-19 Bayer Intellectual Property GmbH New n-(1-methyl-2phenylethyl)benzamide derivatives
US7572823B2 (en) * 2006-02-07 2009-08-11 Hoffmann-La Roche Inc. Heteroaryl carboxamide compounds
US7745477B2 (en) * 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
ES2359744T3 (es) * 2006-02-07 2011-05-26 F. Hoffmann-La Roche Ag Derivados de la benzamida y del heteroareno como inhibidores de la cetp.
US8022217B2 (en) 2006-07-31 2011-09-20 Cadila Healthcare Limited Compounds suitable as modulators of HDL
MX2009005504A (es) 2006-12-07 2009-06-03 Hoffmann La Roche Derivados de espiro piperidina como antagonistas del receptor via.
WO2008077810A2 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
EP2011783A1 (en) * 2007-07-06 2009-01-07 F. Hoffmann-La Roche Ag Process for the preparation of an indole derivative
US20090325717A1 (en) * 2008-06-26 2009-12-31 Marlon John Lee-Him Video Game Controller Holder
WO2010059711A1 (en) * 2008-11-18 2010-05-27 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
CA2768505C (en) * 2009-07-17 2018-06-12 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
CN103038212B (zh) 2010-05-31 2015-04-22 杏林制药株式会社 3-取代-4-氟吡咯烷衍生物的制造方法
BR112013023330B8 (pt) 2011-03-16 2022-09-27 Mitsubishi Tanabe Pharma Corp Compostos de sulfonamida tendo atividade antagonista trpm8
AU2012255690B2 (en) 2011-05-16 2015-06-11 Bionomics Limited Amine derivatives as potassium channel blockers
WO2015054088A1 (en) * 2013-10-10 2015-04-16 Merck Sharp & Dohme Corp. 3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein
AU2014348422B2 (en) 2013-11-15 2019-02-14 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and their method of use
CN113149885A (zh) 2015-05-14 2021-07-23 威斯塔解剖学和生物学研究所 Ebna1抑制剂和使用其的方法
WO2019222470A1 (en) 2018-05-17 2019-11-21 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN113045475A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种5-溴-7-甲基吲哚的制备方法
CN113943238B (zh) 2020-07-17 2022-11-01 沈阳中化农药化工研发有限公司 一种取代的苯硫醚类化合物及其应用
WO2024050408A1 (en) * 2022-08-30 2024-03-07 The Wistar Institute Of Anatomy And Biology Development of a novel ebna-1 degrader targeting through mdm2
CN115417781B (zh) * 2022-09-30 2023-08-29 西安凯立新材料股份有限公司 一种制备氯虫苯甲酰胺中间体k胺的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935992T4 (de) * 1998-09-25 2008-05-29 Monsanto Co., Chicago Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
US7879893B2 (en) * 2001-09-14 2011-02-01 Novo Nordisk A/S Ligands for the HisB10 Zn2 + sites of the R-state insulin hexamer
EP1533292B1 (en) * 2002-08-30 2007-02-14 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
AU2003268550A1 (en) * 2002-09-06 2004-03-29 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives

Also Published As

Publication number Publication date
JP4787254B2 (ja) 2011-10-05
EP1776338A1 (en) 2007-04-25
JP2008508334A (ja) 2008-03-21
WO2006013048A1 (en) 2006-02-09
BRPI0514133A (pt) 2008-05-27
MX2007001431A (es) 2007-04-02
AR050281A1 (es) 2006-10-11
CN1993323B (zh) 2011-04-20
CN1993323A (zh) 2007-07-04
RU2007106180A (ru) 2008-09-10
AU2005268893A1 (en) 2006-02-09
KR20070035096A (ko) 2007-03-29
US7259183B2 (en) 2007-08-21
KR100854864B1 (ko) 2008-08-28
TW200616953A (en) 2006-06-01
US20060030613A1 (en) 2006-02-09
AU2005268893B2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
CA2575329A1 (en) Indole, indazole or indoline derivatives
CA2640662C (en) Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating cetp-mediated disorders
ES2387323T3 (es) Derivados de antranilamida/2-amino-heteroareno-carboxamida
JP4929472B2 (ja) カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AU2007213832B2 (en) Benzamide and heteroarene derivatives as CETP inhibitors
WO2007090748A1 (en) Benzamide and heteroarene derivatives
MXPA03000367A (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
UA70326C2 (en) 2-(3,5-bis-trifluoromethylphenyl)-n-methyl-(6-morp2-(3,5-bis-trifluoromethylphenyl)-n-methyl-(6-morpholine-4-yl-4-tolylpiridine-3-yl)isobutiramide, a holine-4-yl-4-tolylpiridine-3-yl)isobutiramide, a method for the preparation thereof, a pharmaceuticmethod for the preparation thereof, a pharmaceutical preparation and a method for the treatment of dal preparation and a method for the treatment of diseases relating to the nk-1 receptor iseases relating to the nk-1 receptor
KR870001916B1 (ko) 피리딜 화합물의 제조방법
ES2233338T3 (es) Derivados de difenilo.
AU2007213833B2 (en) Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating CETP-mediated disorders
MX2008009918A (es) Trialquilsililbencilaminocarboxiindoles, indazoles e indolinas y su uso en el tratamiento de trastornos mediados por cetp
JPS58134077A (ja) 新規なインド−ル酢酸エステル誘導体及びその製造法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140521